Theresa Louise Werner MD
Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Gynecologic Cancer, Hematologic Oncology
Associate Professor, Division of Oncology, Department of Medicine, University of Utah; Medical Director Clinical Trials Office at Huntsman Cancer Institute
Join to View Full Profile
1950 Circle of HopeClinic 2BSalt Lake City, UT 84112
Phone+1 801-585-0100
Fax+1 801-585-0721
Dr. Werner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Theresa Werner is an oncologist in Salt Lake City, UT and is affiliated with University of Utah Health. She received her medical degree from Indiana University School of Medicine and has been in practice 17 years. She specializes in breast cancer, cancer genetics/cancer risk assessment, gynecologic cancer, and hematologic oncology and is experienced in hematologic oncology, breast cancer, and gynecologic oncology.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2004 - 2007- University of Utah HealthResidency, Internal Medicine, 2000 - 2003
Indiana University School of MedicineClass of 2000
Certifications & Licensure
UT State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
- Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
- Join now to see all
Publications & Presentations
PubMed
- Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.Maj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth, Martin Schønemann-Lund, Gitte-Bettina Nyvang
Cancer Research Communications. 2024-12-01 - 1 citationsSitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, Sanjay Goel, Rebecca Heist
Future Oncology. 2024-12-01 - 1 citationsTargeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer.Shubham Pant, Byoung Chul Cho, Christos E Kyriakopoulos, Alexander Spira, Nizar Tannir
Investigational New Drugs. 2024-10-01
Press Mentions
- Community DeathsMarch 16th, 2021
‘Beacon of Hope’: New Ovarian Cancer Drug Improves Survival Rates, Utah Doctors SayOctober 1st, 2019
Researchers Trace Timeline of Tumor Evolution in Metastatic Breast Cancer PatientsNovember 28th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
